CFTR2: How will it help care?

The Clinical and Functional Translation of CFTR (CFTR2) project presents a novel approach to clinical and functional annotation of mutations identified in disease-causing genes. Phenotype and genotype information on approximately 40,000 cystic fibrosis (CF) patients were collected from registries and large clinics. The disease-liability of the 160 most frequently reported mutations was evaluated by means of a multistage process which involved clinical (sweat chloride average), functional (expression in cell-based systems) and epidemiological (mutation analysis in obligate heterozygotes) steps. The results of this analysis can be consulted in a dedicated website. Data originated by CFTR2 may be valuable in several facets of CF care, including diagnosis, newborn screening, carrier testing, genotype/phenotype correlation and mutation-specific therapeutics.

[1]  M. Rosenfeld,et al.  Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. , 2009, The Journal of pediatrics.

[2]  B. Kerem,et al.  Recommendations for the classification of diseases as CFTR-related disorders. , 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[3]  Manfred Stuhrmann,et al.  Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders – updated European recommendations , 2009, European Journal of Human Genetics.

[4]  Milan Macek,et al.  Benchmarks for cystic fibrosis carrier screening: a European consensus document. , 2010, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[5]  Milan Macek,et al.  Cystic fibrosis: A worldwide analysis of CFTR mutations—correlation with incidence data and application to screening , 2002, Human mutation.

[6]  D. Touw,et al.  Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients. , 2008, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[7]  O. Sommerburg,et al.  European best practice guidelines for cystic fibrosis neonatal screening. , 2009, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[8]  G. Cutting,et al.  The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. , 1998, The Journal of pediatrics.

[9]  Victoria M. Pratt,et al.  Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel , 2004, Genetics in Medicine.

[10]  J. Yankaskas,et al.  Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines. , 2007, The Journal of pediatrics.

[11]  Vicky A Legrys,et al.  Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. , 2008, The Journal of pediatrics.

[12]  M. Corey,et al.  Evaluation of the disease liability of CFTR variants. , 2011, Methods in molecular biology.

[13]  B. Kerem,et al.  Consensus on the Use and Interpretation of Cystic Fibrosis Mutation Analysis in Clinical Practice , 2022 .

[14]  C. Castellani,et al.  A survey of newborn screening for cystic fibrosis in Europe. , 2007, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[15]  C. Ren,et al.  Clinical outcomes in infants with cystic fibrosis transmembrane conductance regulator (CFTR) related metabolic syndrome , 2011, Pediatric pulmonology.